Ahmedabad, Gujarat, May 14, 2026 — Senores Pharmaceuticals Limited reported strong financial and operational performance for the fourth quarter and full year ended March 31, 2026, driven by sustained growth across regulated markets, emerging markets and branded generics businesses.

The research-driven pharmaceutical company posted consolidated total income of ₹664 crore for FY26, marking a 62% year-on-year increase. EBITDA rose 96% to ₹200 crore, while profit after tax (PAT) climbed 108% to ₹122 crore.

For Q4 FY26, total income stood at ₹190 crore, up 58% year-on-year. EBITDA increased 144% to ₹62 crore, while quarterly PAT rose 105% to ₹37 crore, reflecting improved operating leverage and execution.

The company also reported improved operating cash flow generation, with FY26 cash flow from operations reaching ₹75 crore, supported by stronger EBITDA-to-cash conversion.

Regulated Markets Lead Growth

Senores said its regulated markets business remained the key growth driver during the year.

Revenue from regulated markets rose 74.6% year-on-year to ₹427.4 crore in FY26, while Q4 revenue from the segment grew 83% to ₹117.8 crore.

The company now holds 51 approved ANDAs covering 151 strengths, more than double the 26 approved ANDAs it had as of March 2025. More than 30 approved ANDAs are yet to be commercialized, while 27 ANDAs involving over 65 strengths remain under development.

Emerging Markets and Branded Generics Expand

The emerging markets business continued to record steady growth, with FY26 revenue increasing 19.7% year-on-year to ₹145 crore. Q4 revenue from the segment rose 25.8% to ₹45.9 crore. EBITDA margins for the segment stood at approximately 12% during FY26.

Meanwhile, the company’s India-focused branded generics business delivered significant expansion. FY26 revenue surged nearly 385% year-on-year to ₹40 crore, while Q4 revenue rose 132.4% to ₹9.4 crore. The company said its portfolio has received approvals from several leading specialty and multi-specialty hospitals.

Strategic Acquisitions and U.S. Expansion

During FY26, Senores completed several strategic initiatives aimed at strengthening its global platform and improving long-term scalability.

The company completed Phase 1 acquisition of a 75% stake in Apnar Pharmaceuticals, with the remaining 25% expected to be completed by Q2 FY27. Product rollouts from the facility began in Q4 FY26, and the company expects the facility to scale significantly over the next 12 to 18 months while improving margins and expanding CDMO-CMO opportunities.

Senores also signed an agreement to acquire a 51% membership interest in Zoraya Pharmaceuticals LLC in the United States. The platform is expected to support vertical integration and commercialization of the company’s ANDA portfolio in the U.S. market.

In April 2026, the company established Amerisyn, a 70% joint venture in the United States, enabling direct participation in pharmaceutical supply opportunities for federal, veterans and defense sectors.

Management Commentary

Commenting on the performance, Managing Director Swapnil Shah said the company delivered robust growth despite an uncertain operating environment, supported by operational discipline and consistent execution.

Shah noted that the company’s approved ANDA portfolio more than doubled during FY26 and said the combination of approved products, ongoing development pipeline, manufacturing expansion and U.S. commercialization initiatives positions Senores for sustained long-term growth.

Outlook

Senores said it will continue focusing on expanding its regulated market pipeline, strengthening vertical integration, scaling its branded generics portfolio and improving profitability in emerging markets.

The company added that continued investments in product development, manufacturing capacity and global commercialization platforms are expected to support growth momentum in the coming years.